XML 84 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and divestitures - Acquisition of Horizon Therapeutics plc (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 12 Months Ended
Oct. 06, 2023
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]            
Goodwill   $ 18,629 $ 18,629 $ 18,629 $ 15,529 $ 14,890
Horizon Therapeutics            
Business Acquisition [Line Items]            
Acquisition price per share (in usd per share) $ 116.50          
Consideration transferred $ 27,800          
Acquisition related costs     487      
Integration related costs     167      
Acquisition related transaction costs     320      
Cash purchase price 26,700          
Consideration transferred for vested and outstanding awards 523          
Consideration transferred for replacement awards 180          
Liabilities incurred $ 382          
Replacement equity awards issued (in shares) 1.7          
Inventories $ 5,025 5,000 $ 5,000 $ 5,000    
Business combination, turnover period of inventory acquired       27 months    
Deferred tax liabilities 2,492          
Deferred tax asset 834          
Goodwill 3,111          
Revenue of acquiree   955        
Net losses of acquiree   $ 1,200        
Horizon Therapeutics | Fair Value Adjustment to Inventory            
Business Acquisition [Line Items]            
Net losses of acquiree       $ 633    
Horizon Therapeutics | Amortization Of Intangibles Assets            
Business Acquisition [Line Items]            
Net losses of acquiree       $ 479    
Horizon Therapeutics | Developed-product-technology rights            
Business Acquisition [Line Items]            
Estimated fair value $ 20,700          
Weighted average period of amortization 10 years